UPDATE: Jefferies Downgrades Sigilon Therapeutics (SGTX) to Hold

Sigilon Therapeutics Announces Update on SIG-001 Phase 1/2 Study in Hemophilia A

CAMBRIDGE, Mass., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ: SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics platform, today reported that fibrosed spheres were observed during a retrieval procedure in a patient in its Phase 1/2 study of SIG-001 in severe or moderately severe hemophilia A.

The SIG-001 trial had been placed on clinical hold by the FDA in July 2021 following Sigilons submission of a serious adverse event report relating to the development of inhibitors to Factor VIII in one of three patients... More